Efficacy and Safety of Mefloquine, Artesunate, Mefloquine-Artesunate, and Praziquantel against Schistosoma haematobium: Randomized, Exploratory Open-Label Trial
Background. Morbidity control of schistosomiasis relies on a single drug, praziquantel. The antimalarial drug mefloquine possesses interesting antischistosomal properties, yet no clinical studies have been performed. Methods. We conducted a randomized, exploratory open-label trial to assess the effi...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2010-05, Vol.50 (9), p.1205-1213 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1213 |
|---|---|
| container_issue | 9 |
| container_start_page | 1205 |
| container_title | Clinical infectious diseases |
| container_volume | 50 |
| creator | Keiser, Jennifer N'Guessan, Nicaise A. Adoubryn, Koffi D. Silué, Kigbafori D. Vounatsou, Penelope Hatz, Christoph Utzinger, Jürg N'Goran, Eliezer K. |
| description | Background. Morbidity control of schistosomiasis relies on a single drug, praziquantel. The antimalarial drug mefloquine possesses interesting antischistosomal properties, yet no clinical studies have been performed. Methods. We conducted a randomized, exploratory open-label trial to assess the efficacy and safety of mefloquine (25 mg/kg), artesunate (3 doses of 4 mg/kg), mefloquine-artesunate (3 doses of 100 mg artesunate plus 250 mg mefloquine), and praziquantel (40 mg/kg) against Schistosoma haematobium. The effects on Schistosoma mansoni, malaria parasitemia, soil-transmitted helminths, and intestinal protozoa were also determined. Results. A total of 83 S. haematobium-infected schoolchildren were included in the study. Cure rates of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against S. haematobium at day 26 after treatment were 21%, 25%, 61%, and 88%, respectively. Both mefloquine-artesunate and praziquantel resulted in egg reduction rates >95%. Significantly lower egg reduction rates were seen in the artesunate (85%) and mefloquine groups (74%). In children coinfected with S. mansoni, praziquantel and mefloquine-artesunate, but not mefloquine and artesunate alone, resulted in high cure rates and egg reduction rates. Mefloquine, artesunate, and mefloquine-artesunate completely cured infections due to Plasmodium falciparum. No effects were found against soil-transmitted helminths and intestinal protozoa. Abdominal pain was the most frequent adverse event, with a higher incidence among children treated with mefloquine (89%), mefloquine-artesunate (83%), and artesunate (60%) than among children treated with praziquantel (46%). Conclusions. The high efficacy of mefloquine-artesunate against S. haematobium warrants further investigation. Individuals coinfected with Plasmodium and Schistosoma who were treated with a mefloquine-artesunate combination against malaria might have a dual benefit: clearance of malaria parasitemia and reduction of schistosomiasisrelated morbidity. Clinical trials registration. Current Controlled Trials identifier: ISRCTN06498763. |
| doi_str_mv | 10.1086/651682 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_754544025</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>40599098</jstor_id><oup_id>10.1086/651682</oup_id><sourcerecordid>40599098</sourcerecordid><originalsourceid>FETCH-LOGICAL-c449t-b06f776c00728370522722208e7045afb7b851d0f394398d5b3556c433fb70f3</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhSMEoqXAG4AMC9g0cP0XO-yqYdoiDeqImQXqxnIyNvWQxKmdSJ0-DY-Kq5QBISG88dU53z3S1cmy5xjeYZDF-4LjQpIH2SHmVOQFL_HDNAOXOZNUHmRPYtwCYCyBP84OCFAOuGSH2Y-5ta7W9Q7pboNW2pphh7xFn41t_PXoOnOMTsJg4tjpIc2_9fxP-W55GfStux51N5gG6W_adXFAq_rKxcFH32p0pU2rB1-5sf2AvqQV37pbszlG85u-8SFZYYcuetPlC12ljHVwunmaPbK6iebZ_X-UrU_n69l5vrg4-zQ7WeQ1Y-WQV1BYIYoaQBBJBXBCBCEEpBHAuLaVqCTHG7C0ZLSUG15RzouaUZqspB5lb6fYPqTzTBxU62JtmkZ3xo9RCc44Y0D4_0maHmMCEvn6L3Lrx9ClKxTBZcmlECJBbyaoDj7GYKzqg2t12CkM6q5aNVWbwJf3aWPVms0e-9VlAl5NgB_7f4e8mJhtKiXsKQa8LKGUyc8nP5Vmbva-Dt9VIajg6vzrpVqerS5nH_FSndKfFwLAyA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219958777</pqid></control><display><type>article</type><title>Efficacy and Safety of Mefloquine, Artesunate, Mefloquine-Artesunate, and Praziquantel against Schistosoma haematobium: Randomized, Exploratory Open-Label Trial</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Keiser, Jennifer ; N'Guessan, Nicaise A. ; Adoubryn, Koffi D. ; Silué, Kigbafori D. ; Vounatsou, Penelope ; Hatz, Christoph ; Utzinger, Jürg ; N'Goran, Eliezer K.</creator><creatorcontrib>Keiser, Jennifer ; N'Guessan, Nicaise A. ; Adoubryn, Koffi D. ; Silué, Kigbafori D. ; Vounatsou, Penelope ; Hatz, Christoph ; Utzinger, Jürg ; N'Goran, Eliezer K.</creatorcontrib><description>Background. Morbidity control of schistosomiasis relies on a single drug, praziquantel. The antimalarial drug mefloquine possesses interesting antischistosomal properties, yet no clinical studies have been performed. Methods. We conducted a randomized, exploratory open-label trial to assess the efficacy and safety of mefloquine (25 mg/kg), artesunate (3 doses of 4 mg/kg), mefloquine-artesunate (3 doses of 100 mg artesunate plus 250 mg mefloquine), and praziquantel (40 mg/kg) against Schistosoma haematobium. The effects on Schistosoma mansoni, malaria parasitemia, soil-transmitted helminths, and intestinal protozoa were also determined. Results. A total of 83 S. haematobium-infected schoolchildren were included in the study. Cure rates of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against S. haematobium at day 26 after treatment were 21%, 25%, 61%, and 88%, respectively. Both mefloquine-artesunate and praziquantel resulted in egg reduction rates >95%. Significantly lower egg reduction rates were seen in the artesunate (85%) and mefloquine groups (74%). In children coinfected with S. mansoni, praziquantel and mefloquine-artesunate, but not mefloquine and artesunate alone, resulted in high cure rates and egg reduction rates. Mefloquine, artesunate, and mefloquine-artesunate completely cured infections due to Plasmodium falciparum. No effects were found against soil-transmitted helminths and intestinal protozoa. Abdominal pain was the most frequent adverse event, with a higher incidence among children treated with mefloquine (89%), mefloquine-artesunate (83%), and artesunate (60%) than among children treated with praziquantel (46%). Conclusions. The high efficacy of mefloquine-artesunate against S. haematobium warrants further investigation. Individuals coinfected with Plasmodium and Schistosoma who were treated with a mefloquine-artesunate combination against malaria might have a dual benefit: clearance of malaria parasitemia and reduction of schistosomiasisrelated morbidity. Clinical trials registration. Current Controlled Trials identifier: ISRCTN06498763.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/651682</identifier><identifier>PMID: 20350194</identifier><language>eng</language><publisher>United States: The University of Chicago Press</publisher><subject>Abdominal Pain - chemically induced ; Animals ; Anthelmintics - administration & dosage ; Anthelmintics - adverse effects ; Antimalarials ; Artemisinins - administration & dosage ; Artemisinins - adverse effects ; ARTICLES AND COMMENTARIES ; Blood ; Child ; Children ; Clinical trials ; Dosage ; Drug resistance ; Drug Therapy, Combination ; Drugs ; Eggs ; Female ; Humans ; Incidence ; Infections ; Infectious diseases ; Malaria ; Malaria, Falciparum - parasitology ; Male ; Mefloquine - administration & dosage ; Mefloquine - adverse effects ; Morbidity ; Parasite Egg Count ; Parasitic diseases ; Plasmodium falciparum ; Plasmodium falciparum - drug effects ; Praziquantel - administration & dosage ; Praziquantel - adverse effects ; Protozoa ; Schistosoma haematobium ; Schistosoma haematobium - drug effects ; Schistosoma haematobium - isolation & purification ; Schistosoma mansoni ; Schistosomiasis ; Schistosomiasis haematobia - drug therapy ; Treatment Outcome ; Urine</subject><ispartof>Clinical infectious diseases, 2010-05, Vol.50 (9), p.1205-1213</ispartof><rights>2010 Infectious Diseases Society of America</rights><rights>2010 by the Infectious Diseases Society of America 2010</rights><rights>Copyright University of Chicago, acting through its Press May 1, 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c449t-b06f776c00728370522722208e7045afb7b851d0f394398d5b3556c433fb70f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/40599098$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/40599098$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20350194$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Keiser, Jennifer</creatorcontrib><creatorcontrib>N'Guessan, Nicaise A.</creatorcontrib><creatorcontrib>Adoubryn, Koffi D.</creatorcontrib><creatorcontrib>Silué, Kigbafori D.</creatorcontrib><creatorcontrib>Vounatsou, Penelope</creatorcontrib><creatorcontrib>Hatz, Christoph</creatorcontrib><creatorcontrib>Utzinger, Jürg</creatorcontrib><creatorcontrib>N'Goran, Eliezer K.</creatorcontrib><title>Efficacy and Safety of Mefloquine, Artesunate, Mefloquine-Artesunate, and Praziquantel against Schistosoma haematobium: Randomized, Exploratory Open-Label Trial</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><addtitle>Clinical Infectious Diseases</addtitle><description>Background. Morbidity control of schistosomiasis relies on a single drug, praziquantel. The antimalarial drug mefloquine possesses interesting antischistosomal properties, yet no clinical studies have been performed. Methods. We conducted a randomized, exploratory open-label trial to assess the efficacy and safety of mefloquine (25 mg/kg), artesunate (3 doses of 4 mg/kg), mefloquine-artesunate (3 doses of 100 mg artesunate plus 250 mg mefloquine), and praziquantel (40 mg/kg) against Schistosoma haematobium. The effects on Schistosoma mansoni, malaria parasitemia, soil-transmitted helminths, and intestinal protozoa were also determined. Results. A total of 83 S. haematobium-infected schoolchildren were included in the study. Cure rates of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against S. haematobium at day 26 after treatment were 21%, 25%, 61%, and 88%, respectively. Both mefloquine-artesunate and praziquantel resulted in egg reduction rates >95%. Significantly lower egg reduction rates were seen in the artesunate (85%) and mefloquine groups (74%). In children coinfected with S. mansoni, praziquantel and mefloquine-artesunate, but not mefloquine and artesunate alone, resulted in high cure rates and egg reduction rates. Mefloquine, artesunate, and mefloquine-artesunate completely cured infections due to Plasmodium falciparum. No effects were found against soil-transmitted helminths and intestinal protozoa. Abdominal pain was the most frequent adverse event, with a higher incidence among children treated with mefloquine (89%), mefloquine-artesunate (83%), and artesunate (60%) than among children treated with praziquantel (46%). Conclusions. The high efficacy of mefloquine-artesunate against S. haematobium warrants further investigation. Individuals coinfected with Plasmodium and Schistosoma who were treated with a mefloquine-artesunate combination against malaria might have a dual benefit: clearance of malaria parasitemia and reduction of schistosomiasisrelated morbidity. Clinical trials registration. Current Controlled Trials identifier: ISRCTN06498763.</description><subject>Abdominal Pain - chemically induced</subject><subject>Animals</subject><subject>Anthelmintics - administration & dosage</subject><subject>Anthelmintics - adverse effects</subject><subject>Antimalarials</subject><subject>Artemisinins - administration & dosage</subject><subject>Artemisinins - adverse effects</subject><subject>ARTICLES AND COMMENTARIES</subject><subject>Blood</subject><subject>Child</subject><subject>Children</subject><subject>Clinical trials</subject><subject>Dosage</subject><subject>Drug resistance</subject><subject>Drug Therapy, Combination</subject><subject>Drugs</subject><subject>Eggs</subject><subject>Female</subject><subject>Humans</subject><subject>Incidence</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Malaria</subject><subject>Malaria, Falciparum - parasitology</subject><subject>Male</subject><subject>Mefloquine - administration & dosage</subject><subject>Mefloquine - adverse effects</subject><subject>Morbidity</subject><subject>Parasite Egg Count</subject><subject>Parasitic diseases</subject><subject>Plasmodium falciparum</subject><subject>Plasmodium falciparum - drug effects</subject><subject>Praziquantel - administration & dosage</subject><subject>Praziquantel - adverse effects</subject><subject>Protozoa</subject><subject>Schistosoma haematobium</subject><subject>Schistosoma haematobium - drug effects</subject><subject>Schistosoma haematobium - isolation & purification</subject><subject>Schistosoma mansoni</subject><subject>Schistosomiasis</subject><subject>Schistosomiasis haematobia - drug therapy</subject><subject>Treatment Outcome</subject><subject>Urine</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1DAUhSMEoqXAG4AMC9g0cP0XO-yqYdoiDeqImQXqxnIyNvWQxKmdSJ0-DY-Kq5QBISG88dU53z3S1cmy5xjeYZDF-4LjQpIH2SHmVOQFL_HDNAOXOZNUHmRPYtwCYCyBP84OCFAOuGSH2Y-5ta7W9Q7pboNW2pphh7xFn41t_PXoOnOMTsJg4tjpIc2_9fxP-W55GfStux51N5gG6W_adXFAq_rKxcFH32p0pU2rB1-5sf2AvqQV37pbszlG85u-8SFZYYcuetPlC12ljHVwunmaPbK6iebZ_X-UrU_n69l5vrg4-zQ7WeQ1Y-WQV1BYIYoaQBBJBXBCBCEEpBHAuLaVqCTHG7C0ZLSUG15RzouaUZqspB5lb6fYPqTzTBxU62JtmkZ3xo9RCc44Y0D4_0maHmMCEvn6L3Lrx9ClKxTBZcmlECJBbyaoDj7GYKzqg2t12CkM6q5aNVWbwJf3aWPVms0e-9VlAl5NgB_7f4e8mJhtKiXsKQa8LKGUyc8nP5Vmbva-Dt9VIajg6vzrpVqerS5nH_FSndKfFwLAyA</recordid><startdate>20100501</startdate><enddate>20100501</enddate><creator>Keiser, Jennifer</creator><creator>N'Guessan, Nicaise A.</creator><creator>Adoubryn, Koffi D.</creator><creator>Silué, Kigbafori D.</creator><creator>Vounatsou, Penelope</creator><creator>Hatz, Christoph</creator><creator>Utzinger, Jürg</creator><creator>N'Goran, Eliezer K.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>7TN</scope><scope>7U2</scope><scope>F1W</scope><scope>H95</scope><scope>H97</scope><scope>L.G</scope></search><sort><creationdate>20100501</creationdate><title>Efficacy and Safety of Mefloquine, Artesunate, Mefloquine-Artesunate, and Praziquantel against Schistosoma haematobium: Randomized, Exploratory Open-Label Trial</title><author>Keiser, Jennifer ; N'Guessan, Nicaise A. ; Adoubryn, Koffi D. ; Silué, Kigbafori D. ; Vounatsou, Penelope ; Hatz, Christoph ; Utzinger, Jürg ; N'Goran, Eliezer K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c449t-b06f776c00728370522722208e7045afb7b851d0f394398d5b3556c433fb70f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Abdominal Pain - chemically induced</topic><topic>Animals</topic><topic>Anthelmintics - administration & dosage</topic><topic>Anthelmintics - adverse effects</topic><topic>Antimalarials</topic><topic>Artemisinins - administration & dosage</topic><topic>Artemisinins - adverse effects</topic><topic>ARTICLES AND COMMENTARIES</topic><topic>Blood</topic><topic>Child</topic><topic>Children</topic><topic>Clinical trials</topic><topic>Dosage</topic><topic>Drug resistance</topic><topic>Drug Therapy, Combination</topic><topic>Drugs</topic><topic>Eggs</topic><topic>Female</topic><topic>Humans</topic><topic>Incidence</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Malaria</topic><topic>Malaria, Falciparum - parasitology</topic><topic>Male</topic><topic>Mefloquine - administration & dosage</topic><topic>Mefloquine - adverse effects</topic><topic>Morbidity</topic><topic>Parasite Egg Count</topic><topic>Parasitic diseases</topic><topic>Plasmodium falciparum</topic><topic>Plasmodium falciparum - drug effects</topic><topic>Praziquantel - administration & dosage</topic><topic>Praziquantel - adverse effects</topic><topic>Protozoa</topic><topic>Schistosoma haematobium</topic><topic>Schistosoma haematobium - drug effects</topic><topic>Schistosoma haematobium - isolation & purification</topic><topic>Schistosoma mansoni</topic><topic>Schistosomiasis</topic><topic>Schistosomiasis haematobia - drug therapy</topic><topic>Treatment Outcome</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Keiser, Jennifer</creatorcontrib><creatorcontrib>N'Guessan, Nicaise A.</creatorcontrib><creatorcontrib>Adoubryn, Koffi D.</creatorcontrib><creatorcontrib>Silué, Kigbafori D.</creatorcontrib><creatorcontrib>Vounatsou, Penelope</creatorcontrib><creatorcontrib>Hatz, Christoph</creatorcontrib><creatorcontrib>Utzinger, Jürg</creatorcontrib><creatorcontrib>N'Goran, Eliezer K.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Oceanic Abstracts</collection><collection>Safety Science and Risk</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Keiser, Jennifer</au><au>N'Guessan, Nicaise A.</au><au>Adoubryn, Koffi D.</au><au>Silué, Kigbafori D.</au><au>Vounatsou, Penelope</au><au>Hatz, Christoph</au><au>Utzinger, Jürg</au><au>N'Goran, Eliezer K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and Safety of Mefloquine, Artesunate, Mefloquine-Artesunate, and Praziquantel against Schistosoma haematobium: Randomized, Exploratory Open-Label Trial</atitle><jtitle>Clinical infectious diseases</jtitle><stitle>Clinical Infectious Diseases</stitle><addtitle>Clinical Infectious Diseases</addtitle><date>2010-05-01</date><risdate>2010</risdate><volume>50</volume><issue>9</issue><spage>1205</spage><epage>1213</epage><pages>1205-1213</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Background. Morbidity control of schistosomiasis relies on a single drug, praziquantel. The antimalarial drug mefloquine possesses interesting antischistosomal properties, yet no clinical studies have been performed. Methods. We conducted a randomized, exploratory open-label trial to assess the efficacy and safety of mefloquine (25 mg/kg), artesunate (3 doses of 4 mg/kg), mefloquine-artesunate (3 doses of 100 mg artesunate plus 250 mg mefloquine), and praziquantel (40 mg/kg) against Schistosoma haematobium. The effects on Schistosoma mansoni, malaria parasitemia, soil-transmitted helminths, and intestinal protozoa were also determined. Results. A total of 83 S. haematobium-infected schoolchildren were included in the study. Cure rates of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against S. haematobium at day 26 after treatment were 21%, 25%, 61%, and 88%, respectively. Both mefloquine-artesunate and praziquantel resulted in egg reduction rates >95%. Significantly lower egg reduction rates were seen in the artesunate (85%) and mefloquine groups (74%). In children coinfected with S. mansoni, praziquantel and mefloquine-artesunate, but not mefloquine and artesunate alone, resulted in high cure rates and egg reduction rates. Mefloquine, artesunate, and mefloquine-artesunate completely cured infections due to Plasmodium falciparum. No effects were found against soil-transmitted helminths and intestinal protozoa. Abdominal pain was the most frequent adverse event, with a higher incidence among children treated with mefloquine (89%), mefloquine-artesunate (83%), and artesunate (60%) than among children treated with praziquantel (46%). Conclusions. The high efficacy of mefloquine-artesunate against S. haematobium warrants further investigation. Individuals coinfected with Plasmodium and Schistosoma who were treated with a mefloquine-artesunate combination against malaria might have a dual benefit: clearance of malaria parasitemia and reduction of schistosomiasisrelated morbidity. Clinical trials registration. Current Controlled Trials identifier: ISRCTN06498763.</abstract><cop>United States</cop><pub>The University of Chicago Press</pub><pmid>20350194</pmid><doi>10.1086/651682</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2010-05, Vol.50 (9), p.1205-1213 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_754544025 |
| source | Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Abdominal Pain - chemically induced Animals Anthelmintics - administration & dosage Anthelmintics - adverse effects Antimalarials Artemisinins - administration & dosage Artemisinins - adverse effects ARTICLES AND COMMENTARIES Blood Child Children Clinical trials Dosage Drug resistance Drug Therapy, Combination Drugs Eggs Female Humans Incidence Infections Infectious diseases Malaria Malaria, Falciparum - parasitology Male Mefloquine - administration & dosage Mefloquine - adverse effects Morbidity Parasite Egg Count Parasitic diseases Plasmodium falciparum Plasmodium falciparum - drug effects Praziquantel - administration & dosage Praziquantel - adverse effects Protozoa Schistosoma haematobium Schistosoma haematobium - drug effects Schistosoma haematobium - isolation & purification Schistosoma mansoni Schistosomiasis Schistosomiasis haematobia - drug therapy Treatment Outcome Urine |
| title | Efficacy and Safety of Mefloquine, Artesunate, Mefloquine-Artesunate, and Praziquantel against Schistosoma haematobium: Randomized, Exploratory Open-Label Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T16%3A17%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20Safety%20of%20Mefloquine,%20Artesunate,%20Mefloquine-Artesunate,%20and%20Praziquantel%20against%20Schistosoma%20haematobium:%20Randomized,%20Exploratory%20Open-Label%20Trial&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Keiser,%20Jennifer&rft.date=2010-05-01&rft.volume=50&rft.issue=9&rft.spage=1205&rft.epage=1213&rft.pages=1205-1213&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1086/651682&rft_dat=%3Cjstor_proqu%3E40599098%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219958777&rft_id=info:pmid/20350194&rft_jstor_id=40599098&rft_oup_id=10.1086/651682&rfr_iscdi=true |